365 related articles for article (PubMed ID: 25350226)
1. Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010).
Macalalad AR; Hao Y; Lin PL; Signorovitch JE; Wu EQ; Ohashi E; Zhou Z; Kelley C
Curr Med Res Opin; 2015 Feb; 31(2):263-73. PubMed ID: 25350226
[TBL] [Abstract][Full Text] [Related]
2. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
3. Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study.
Goldschmidt D; Dalal AA; Romdhani H; Kelkar S; Guerin A; Gauthier G; Wu EQ; Niravath P; Small T
Adv Ther; 2018 Apr; 35(4):482-493. PubMed ID: 29582246
[TBL] [Abstract][Full Text] [Related]
4. Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician survey.
Lin PL; Hao Y; Xie J; Li N; Zhong Y; Zhou Z; Signorovitch JE; Wu EQ
Cancer Med; 2016 Feb; 5(2):209-20. PubMed ID: 26686532
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.
Xie J; Hao Y; Li N; Lin PL; Ohashi E; Koo V; Signorovitch JE; Wu EQ; Yardley DA
Curr Med Res Opin; 2015 Jun; 31(6):1095-103. PubMed ID: 25971725
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.
Guérin A; Hao Y; Tang D; Peeples M; Fang A; Kageleiry A; Koo V; Li N; Wu EQ
Expert Opin Pharmacother; 2016 Jun; 17(9):1189-96. PubMed ID: 27052735
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2- Metastatic Breast Cancer.
Guérin A; Goldschmidt D; Small T; Gagnon-Sanschagrin P; Romdhani H; Gauthier G; Kelkar S; Wu EQ; Niravath P; Dalal AA
Adv Ther; 2018 Aug; 35(8):1251-1264. PubMed ID: 29946797
[TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA.
Lin PL; Hao Y; Xie J; Li N; Ohashi E; Koo V; Wu EQ
Expert Opin Pharmacother; 2015; 16(14):2101-11. PubMed ID: 26290278
[TBL] [Abstract][Full Text] [Related]
9. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
[TBL] [Abstract][Full Text] [Related]
10. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.
Wilson FR; Varu A; Mitra D; Cameron C; Iyer S
Breast Cancer Res Treat; 2017 Nov; 166(1):167-177. PubMed ID: 28752187
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study.
Le Saux O; Lardy-Cleaud A; Frank S; Debled M; Cottu PH; Pistilli B; Vanlemmens L; Leheurteur M; Lévy C; Laborde L; Uwer L; D'hondt V; Berchery D; Lorgis V; Ferrero JM; Perrocheau G; Courtinard C; Mouret-Reynier MA; Velten M; Breton M; Parent D; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2019 Sep; 118():131-141. PubMed ID: 31330488
[TBL] [Abstract][Full Text] [Related]
12. Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer.
Li N; Hao Y; Xie J; Lin PL; Zhou Z; Zhong Y; Signorovitch JE; Wu EQ
Curr Med Res Opin; 2015 Aug; 31(8):1573-82. PubMed ID: 26074049
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
Quek RGW; Mardekian J
Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
[TBL] [Abstract][Full Text] [Related]
14. Patient database analysis of fulvestrant 500 mg in the treatment of metastatic breast cancer: A European perspective.
Marchetti P; Maass N; Gligorov J; Berger K; MacDougall F; Montonen J; Lewis J
Breast; 2017 Apr; 32():247-255. PubMed ID: 28011074
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
16. Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer.
Chen XL; Du F; Hong RX; Wang JY; Luo Y; Li Q; Fan Y; Xu BH
Chin J Cancer; 2016 Apr; 35():39. PubMed ID: 27112139
[TBL] [Abstract][Full Text] [Related]
17. First-line treatment disruption among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.
Tang DH; Li N; Du EX; Peeples M; Chu L; Xie J; Barghout V
Curr Med Res Opin; 2017 Dec; 33(12):2137-2143. PubMed ID: 28994315
[TBL] [Abstract][Full Text] [Related]
18. Clinical and economic outcomes by first-line treatment among women with HR+/HER2- metastatic breast cancer in a large US health plan database.
Burton T; Byfield SD; Smith GL; Zanotti G; Bell TJ; Perkins JJ; Horblyuk R; Teitelbaum A
Curr Med Res Opin; 2016 Aug; 32(8):1417-23. PubMed ID: 27074160
[TBL] [Abstract][Full Text] [Related]
19. Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer:: A Network Meta-analysis.
Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
Clin Ther; 2018 Apr; 40(4):628-639.e3. PubMed ID: 29609880
[TBL] [Abstract][Full Text] [Related]
20. Real-world effectiveness of fulvestrant monotherapy as first endocrine treatment in patients with metastatic breast cancer.
Skinner KE; Olufade T; Walker MS; Schwartzberg LS
Breast J; 2020 Feb; 26(2):112-119. PubMed ID: 31531938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
